PYMXQ News Alert Polymedix Inc (PYMXQ) 0.0201 09/27/2014 21:

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Polymedix Inc (PYMXQ) 0.0201 $PYMXQ

Macular Degeneration - Pipeline Review, H2 2013 Gives an Overview of Pipeline Products for Macular Degeneration
M2 - Wed Sep 04, 12:19PM CDT
Research and Markets (http://www.researchandmarkets.com/research/wv3x9q/macular) has announced the addition of the "Macular Degeneration - Pipeline Review, H2 2013" report to their offering. Global Markets Direct's, 'Macular Degeneration - Pipeline Review, H2 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Macular Degeneration, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Macular Degeneration. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - A snapshot of the global therapeutic scenario for Macular Degeneration. - A review of the Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages. - A feature on pipeline projects on the basis of monotherapy and combined therapeutics. - Coverage of the Macular Degeneration pipeline on the basis of route of administration and molecule type. - Key discontinued pipeline projects. - Latest news and deals relating to the products. Companies Mentioned: Normal 0 false false false MicrosoftInternetExplorer4 Alcon, Inc. Genzyme Corporation Johnson & Johnson F. Hoffmann-La Roche Ltd. Bausch & Lomb Incorporated Allergan, Inc. Shionogi & Co., Ltd. pSivida Corp. Advanced Cell Technology, Inc. GlaxoSmithKline plc Genentech, Inc. Quark Pharmaceuticals, Inc. Pfizer Inc. iCo Therapeutics Inc. Lpath, Inc. Mesoblast Ltd BioDiem Ltd Summit Corporation plc ThromboGenics NV PolyMedix, Inc. e-Therapeutics plc NanoCarrier Co., Ltd. R-Tech Ueno, Ltd. Intellect Neurosciences, Inc. Omeros Corporation Angstrom Pharmaceuticals, Inc. Targa Therapeutics Corp. Pfenex Inc. SelectX Pharmaceuticals, Inc. Icon Bioscience, Inc. EyeGene, Inc. Varinel, Inc. For more information visit http://www.researchandmarkets.com/research/wv3x9q/macula About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013
M2 - Wed Jun 19, 10:02AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5dnrjr/methicillinsuscep) has announced the addition of the "Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013" report to their offering. 'Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. M Scope - A snapshot of the global therapeutic scenario for Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections. - A review of the Methicillin-Susceptible Staphylococcus Aureus (MSSA) Infections products under development by companies and unive

Global Respiratory Tract Infections Report - Pipeline Review, H1 2013 Edition
M2 - Thu Jun 06, 10:04AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hml3h6/respiratory_tract) has announced the addition of the "Respiratory Tract Infections - Pipeline Review, H1 2013" report to their offering. 'Respiratory Tract Infections - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Tract Infections, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Infections. Scope - A snapshot of the global therapeutic scenario for Respiratory Tract Infections. - A review of the Respiratory Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources. - Coverage of products based on various stages of development ranging from discovery till registration stages.

Anthrax - Pipeline Review, H1 2013 Provides Coverage of the Anthrax Pipeline on the Basis of Route of Administration and Molecule Type
M2 - Tue Jun 04, 12:04PM CDT
Research and Markets (http://www.researchandmarkets.com/research/5ssbkc/anthrax) has announced the addition of the "Anthrax - Pipeline Review, H1 2013" report to their offering. Global Markets Direct's, 'Anthrax - Pipeline Review, H1 2013', provides an overview of the indication's therapeutic pipeline. This report provides information on the therapeutic development for Anthrax, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Anthrax. Anthrax - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Scope - A snapshot of the global therapeutic scenario for Anthrax. - A review of the Anthrax products under development




Scroll down for more posts ▼

Top 10 Most Recent News Articles

RMT’s 12.4% Discount Still Demands a Much Harder Look

Updated Category News Views 119

A $1.84 gap is staring RMT shareholders right in the face. As of October 31, 2026, Royce Micro-Cap Trust carried a net asset value of $14.82 per share while the market price sat at $12.98. That is roughly a 12.4% discount to NAV, and closed-end fund investors should never wave off a spread like that with a lazy shrug. It may be opportunity. It may also be the market...

Continue Reading
Liquidity Services Faces a Brutal Revenue Reality Check

Updated Category News Views 23

A 19.17% opening haircut is the market ringing the fire alarm, not politely clearing its throat. Liquidity Services reported fiscal fourth-quarter revenue of $106.4 million, roughly 10% below the prior-year quarter, and shareholders got hit hard on November 19, 2026. That reaction is ugly, but it is not mysterious. When a company built around moving surplus inventory...

Continue Reading
IDEMIA Lands Sweden's Critical 5G Connectivity Job

Updated Category News Views 119

A hospital monitor going dark because a device was misprovisioned is not the kind of connectivity hiccup anybody gets to shrug off. That is why IDEMIA Secure Transactions winning the Region Västra Götaland assignment deserves more attention than the usual telecom plumbing announcement. The region is building what it calls Sweden's largest private 5G network, and the job...

Continue Reading
CustomerInsights.AI Fast 500 Nod Tests Its AI Model

Updated Category News Views 62

Pharma’s analytics mess is exactly where CustomerInsights.AI has chosen to make its stand. The Scottsdale company’s inclusion in Deloitte’s 2026 Technology Fast 500, announced November 19, is a useful signal that its pitch is finding buyers: life-sciences businesses want AI to do actual commercial work, not sit in a lab demo collecting dust. Still, a Fast 500 badge...

Continue Reading
TCL CSOT's Oxide Leap Gives LCD a Sharper Fight Ahead

Updated Category News Views 26

Fifty-one point six is the number that makes this announcement worth chewing on. TCL CSOT says it has moved ultrahigh-mobility oxide technology into mass production on an 8.6-generation line, clearing the 50 cm² V?¹ s?¹ threshold that has largely belonged to lab-talk and presentation slides. For display people, that is not decorative science. It could change the old...

Continue Reading
Retainers Are the Unflashy Finish to Orthodontic Care

Updated Category News Views 103

A straight smile has an inconvenient habit of remembering where it came from. That is the plainspoken point in Dr. Michael McClain’s discussion of retainers after braces or Invisalign: the dramatic part of orthodontic treatment may be over when appliances come off, but the maintenance phase has barely started. It is not glamorous, and plenty of people probably wish it...

Continue Reading
Prospera’s DFW Culture Win Matters Beyond the Plaque

Updated Category News Views 20

Employee survey ballots rarely make pulses race, but this one deserves more than a lazy shrug. Prospera Financial Services has landed on The Dallas Morning News’ 2026 Top Workplaces DFW list for a second consecutive year, placing in the Top Small Workplaces category. For a boutique independent broker-dealer, that is not meaningless wall décor. The people doing the...

Continue Reading
Blue Moon Closes Turner Deal, Eyes Nevada Mill Plan

Updated Category News Views 75

A shuttered Oregon copper-gold deposit just became part of Blue Moon’s puzzle, and the real question is whether the pieces can ever be made to fit cheaply enough to matter. Turner Adds a Nearby VMS Angle Blue Moon Metals has completed its acquisition of the Turner copper-gold deposit in O’Brien, Oregon, from Gold Coast Mining. The formal closing follows the September...

Continue Reading
AI Forces Learning Teams to Redefine Their Core Job

Updated Category News Views 108

Training Departments Are Not Sitting Still Corporate learning has spent years being treated like the office instruction manual, and AI is making that old arrangement look awfully flimsy. RedThread Research's November 19, 2026 study lands on a point that ought to make senior management pay attention: learning and development leaders are not merely waiting around to be...

Continue Reading
Green Lumber Recall Raises a Serious Safety Question

Updated Category News Views 41

A blister-pack code is doing far more work than it ever should. Green Lumber Holdings is recalling Green Lumber Natural Fuel For Men, lot GL01 with expiration 09/27, after FDA laboratory analysis confirmed undeclared tadalafil in additional samples. The company says the consumer-level recall begins November 19, 2026. This is not a cute labeling nitpick or a marketing...

Continue Reading

Top 5 Most Recently Viewed Articles

Harnessing AI for a Transformative Future in Human Resources

Updated Category News Views 193

The Impact of AI on Human Resources in 2026 As we look towards the future of work in 2026, the influence of artificial intelligence (AI) on human resources (HR) is undeniable. Businesses worldwide are adapting to an ecosystem increasingly shaped by AI, which plays a critical role in improving workforce efficiency. With insights from industry experts at ADP, organizations...

Continue Reading
Collins Aerospace Expands Executive Aircraft Seating Operations

Updated Category News Views 110

Collins Aerospace Expands Executive Aircraft Seating Operations Doubled production floor space and new machinery improves capacity and customization opportunities Collins Aerospace, a business unit of RTX (NYSE: RTX), is enhancing its executive aircraft seating facility with a significant $2 million investment. This expansion doubles the upholstery production floor space...

Continue Reading
Celebrating Success: Beyond Finance's Commitment to Clients

Updated Category News Views 345

Beyond Finance's Recognition for Outstanding Customer Service Beyond Finance, a leading name in the debt consolidation sector, proudly received the 2025 Excellence in Customer Service Award from the Business Intelligence Group. This accolade highlights the organization's unwavering commitment to transforming the lives of its clients by providing exceptional onboarding and...

Continue Reading
Understanding Bitcoin's Recent Price Fluctuations and Trends

Updated Category News Views 387

Bitcoin Faces Recent Price Challenges Bitcoin has experienced a 6% drop over the past month; nonetheless, it continues to be in a macro bull market. This resilience makes it outperform many other investment options as the cryptocurrency world evolves. What To Make of Recent Market Trends? Understanding Market Dynamics Notable crypto analyst Ali Martinez has pointed out...

Continue Reading
Chudnovsky Law Welcomes Brian D. Bill as New License Defense Attorney

Updated Category News Views 151

Chudnovsky Law's New Addition: Brian D. Bill Brian D. Bill has recently joined Chudnovsky Law, a distinguished law firm specializing in professional license defense. With California housing over 4.3 million licensed professionals, the need for expert defense in license investigations and enforcement cases is crucial. Brian D. Bill's Legal Background Mr. Bill brings...

Continue Reading